REFERENCES
- Wolfgang GH, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol. 1994; 22: 73–79
- Martinez F, Deray G, Dubois M, et al. Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs. 1993; 4: 85–90
- Stohr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007; 48: 140–147
- Agraharkar M, Nerenstone S, Palmisano J, Kaplan AA. Carboplatin-related hematuria and acute renal failure. Am J Kidney Dis. 1998; 32: E5
- Inbar M, Merimsky O, Chaitchik S. Carboplatin-related idiosyncrasy. Anticancer Drugs. 1995; 6: 775–776
- McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: A report of two cases and review of the literature. Am J Med. 1991; 90: 386–391
- Teo PML, Leung SF, Yu P, Tsao SY, Foo W, Shiu W. A comparison of Ho's, International Union against Cancer, and American Joint Committee Stage Classifications for nasopharyngeal carcinoma. Cancer. 1991; 67: 434–439
- Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17: 409–422
- Frenkel J, Kool G, de Kraker J. Acute renal failure in high dose carboplatin chemotherapy. Med Pediatr Oncol. 1995; 25: 473–474
- Deray G, Ben-Othman T, Brillet G, et al. Carboplatin-induced acute renal failure. Am J Nephrol. 1990; 10: 431–432
- Wright JE, Elias A, Tretyakov O, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995; 36: 345–351
- Squibb Bristol-Myers. Paraplatin-AQ product monograph. Princeton, NJ January, 2004
- Butani L, West DC, Taylor DS. End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation. Pediatr Transplant. 2003; 7: 408–412
- Karim M, Vaux E, Davies DR, Mason PD. Renal failure due to scleroderma with thrombotic microangiopathy developing in a woman treated with carboplatin for ovarian cancer. Clin Nephrol. 2002; 58: 384–388
- Thomas H, Boddy AV, English MW, et al. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial. J Clin Oncol. 2000; 18: 3614–3621